Here is the design of a clinical trial:

Official Title: A Multicentre, Open-label, Randomised, Controlled Study of Target Therapy Based on Tumor Molecular Profiling With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA.

Included conditions:
- Gallbladder Carcinoma

Study Armgroups:
- {'label': 'Afatinib with GEMOX', 'type': 'EXPERIMENTAL', 'description': 'Patients will receive targeted therapy(Afatinib 40mg orally from day 1 to day 21 combined with GEMOX chemotherapy(gemcitabine 1000 mg/m2 on days 1 and 8 of each cycle by IV infusion and oxaliplatin 100 mg/m2 on day 1 of each cycle by IV infusion)', 'interventionNames': ['Drug: gemcitabine and oxaliplatin.', 'Drug: Afatinib']}
- {'label': 'GEMOX', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients will receive conventional GEMOX chemotherapy (gemcitabine 1000 mg/m2 on days 1 and 8 of each cycle by IV infusion and oxaliplatin 100 mg/m2 on day 1 of each cycle by IV infusion）', 'interventionNames': ['Drug: gemcitabine and oxaliplatin.']}

Interventions:
- {'type': 'DRUG', 'name': 'gemcitabine and oxaliplatin.', 'description': 'GEMOX Conventional chemotherapy:gemcitabine and oxaliplatin.', 'armGroupLabels': ['Afatinib with GEMOX', 'GEMOX'], 'otherNames': ['Gemzar(Eli Lilly and Company) and Aiheng(Jiangsu Hengrui Medicine Co., Ltd.)']}
- {'type': 'DRUG', 'name': 'Afatinib', 'description': 'Target therapy Drug: afatinib', 'armGroupLabels': ['Afatinib with GEMOX'], 'otherNames': ['Gilotrif(Boehringer-Ingelheim)']}

Primary Outcomes:
- {'measure': '3-year DFS', 'description': '3-year disease free survival rates:The progression is defined consistent with contrast enhanced MRI/CT.', 'timeFrame': 'up to 3 years'}

Please estimate the sample size based on the assumption: 
The trial is designed with a two-sided significance alpha level of 0.05, an estimated 90% power, and a 10% dropout rate.
Sample size calculation
          We expect that the 3-year DFS rate for patients in the experimental group can rise to about 52% given that the study indicates that the 3-year DFS rate for patients with GBC in the control group is approximately 21%.13 14 28 The trial is designed with a two-sided significance alpha level of 0.05 and an estimated 90% power. Calculated by PASS 11, this trial requires 46 patients to be enrolled in each group. Considering a 10% drop-off rate, a total sample size of 102 is required in order to have a 90% probability of drawing a conclusive conclusion about the difference in the 3-year DFS rate between two groups.
          The annual average number of visits for resectable GBC is about 40 in each hospital and the frequency of ErbB pathway mutations is roughly 36.8%. About 59 patients from 4 hospitals are expected to have GBC with ErbB pathway mutations each year. Within 3âyears, it is anticipated that at least 102 patients will have signed up for the study, taking into account factors for all potential reasons for non-participation, such as patient refusal or abrupt termination.